Given that some BRAF-mutant melanoma patients fail to respond to BRAF inhibitors, and that the majority of patients who do respond to BRAF/MEK inhibitors eventually develop resistance, there is an urgent need to identify possible combination treatments that may be effective. Here, MAP2K7 is linked to melanoma.